The main area of interest of this dissertation was to establish the mechanism of action of the hypolipidaemic drug, fenofibrate. Rats were treated with fenofibrate in the diet to provide intakes of 13, 60 or 200mg/kg/body weight/day for periods varying from 24 hours up to 18 months. Clofibrate (400mg/kg/body weight/day) served as a positive control. Groups of animals were killed at intervals during the course of the study. The aim was to establish the time course and dose response relationship of changes observed in the liver and plasma and to relate these to the morphological effects seen. The results indicated that the accumulation of fat within the liver is subsequently linked to an induction of enzymes responsible for the metabolism of ...
Kompleks dehydrogenazy α-ketoglutaranowej (OGDHC) wraz z kompleksem dehydrogenazy pirogronianowej (P...
AbstractOleoylethanolamine (OEA), an endogenous high-affinity agonist of peroxisome proliferator-act...
Fibrates are hypolipidemic drugs that activate the peroxisome proliferator-activated receptors. Sinc...
The main area of interest of this dissertation was to establish the mechanism of action of the hypol...
The mechanism of induction of peroxisome proliferation by xenobiotics was investigated. Firstly, the...
The liver plays a central role in the production and metabolism of lipoproteins, with adipose tissue...
Introduction. Fenofibrate (FN) is a hypolipemic drug used for the treatment of mixed dyslipidemia. S...
An ultrastructural and biochemical study of the toxic and hypoglycaemic effects of hypoglycin and pe...
AbstractFenofibrate, the hypolipidemic drug and peroxisome proliferator, was given to mice (0.23% w/...
The effects of di-2 ethylhexyl phthalate (DEHP) over periods of 3 days to 9 months were examined in ...
AbstractFenofibrate, the hypolipidemic drug and peroxisome proliferator, was given to mice (0.23% w/...
Objective: To observe the histomorphological changes in liver of Albino wistar rats induced by Fluor...
The morphological and cytochemical changes occurring in liver of male Sprague-Dawley rats receiving ...
The morphological and cytochemical changes occurring in liver of male Sprague-Dawley rats receiving ...
Male and female rats were treated with hypolipidemic agents derived from procetofenic acid, namely f...
Kompleks dehydrogenazy α-ketoglutaranowej (OGDHC) wraz z kompleksem dehydrogenazy pirogronianowej (P...
AbstractOleoylethanolamine (OEA), an endogenous high-affinity agonist of peroxisome proliferator-act...
Fibrates are hypolipidemic drugs that activate the peroxisome proliferator-activated receptors. Sinc...
The main area of interest of this dissertation was to establish the mechanism of action of the hypol...
The mechanism of induction of peroxisome proliferation by xenobiotics was investigated. Firstly, the...
The liver plays a central role in the production and metabolism of lipoproteins, with adipose tissue...
Introduction. Fenofibrate (FN) is a hypolipemic drug used for the treatment of mixed dyslipidemia. S...
An ultrastructural and biochemical study of the toxic and hypoglycaemic effects of hypoglycin and pe...
AbstractFenofibrate, the hypolipidemic drug and peroxisome proliferator, was given to mice (0.23% w/...
The effects of di-2 ethylhexyl phthalate (DEHP) over periods of 3 days to 9 months were examined in ...
AbstractFenofibrate, the hypolipidemic drug and peroxisome proliferator, was given to mice (0.23% w/...
Objective: To observe the histomorphological changes in liver of Albino wistar rats induced by Fluor...
The morphological and cytochemical changes occurring in liver of male Sprague-Dawley rats receiving ...
The morphological and cytochemical changes occurring in liver of male Sprague-Dawley rats receiving ...
Male and female rats were treated with hypolipidemic agents derived from procetofenic acid, namely f...
Kompleks dehydrogenazy α-ketoglutaranowej (OGDHC) wraz z kompleksem dehydrogenazy pirogronianowej (P...
AbstractOleoylethanolamine (OEA), an endogenous high-affinity agonist of peroxisome proliferator-act...
Fibrates are hypolipidemic drugs that activate the peroxisome proliferator-activated receptors. Sinc...